Nul will use the funding to support its full commercial launch in the UK, expand its clinical and product teams, scale customer acquisition, and prepare for future international expansion.
Nul, a UK-based healthtech startup developing a supported alcohol reduction platform that combines clinical care and prescription medication, has raised $1 million in seed funding. The round was led by dmg ventures and BYVP, with participation from a group of angel investors.
Alcohol use disorder and harmful drinking affect millions of people globally, while treatment options have seen limited innovation in recent decades. Nul aims to address this gap with medication- and therapy-supported reduction models designed for individuals who want to reduce their alcohol consumption without requiring immediate or complete abstinence.
Founded by Matus Maar, Nul is building a telehealth platform that integrates clinical care, prescription medication, digital treatment pathways, and behavioural support. The company’s programme is based on naltrexone, a medication used to reduce alcohol cravings by targeting reward pathways.
Delivered through a fully remote subscription service, the programme includes virtual consultations, ongoing clinical support, and structured digital guidance based on The Sinclair Method.
Commenting on the company’s mission, Matus Maar, founder and CEO of Nul, said that alcohol reduction remains one of the largest areas in healthcare that has seen relatively limited modernisation.
Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.
Nul launched a UK test phase in summer 2025 and has onboarded more than 120 paying customers, reaching an annualised revenue run rate of over £300,000 within its first months, driven largely by organic demand and word-of-mouth.
The seed funding will support the company’s full UK commercial launch, expansion of its clinical and product teams, scaling of customer acquisition, and preparation for future international expansion, including the US market.
Alongside the seed round, Nul plans to launch a crowdfunding campaign on Republic Europe, allowing retail investors to participate in the round and support the company’s next phase of growth.